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In 2018, 52 of 55 European and Central Asian coun-
tries reported data against the UNAIDS 90–90–90 
targets. Overall, 80% of people living with HIV (PLHIV) 
were diagnosed, of whom 64% received treatment and 
86% treated were virally suppressed. Subregional out-
comes varied: West (87%–91%–93%), Centre (83%–
73%–75%) and East (76%–46%–78%). Overall, 43% of 
all PLHIV were virally suppressed; intensive efforts are 
needed to meet the 2020 target of 73%.
In 2014, the Joint United National Programme on HIV/
AIDS (UNAIDS) established the global 90–90–90 tar-
gets. The aim was for 90% of all people living with 
HIV (PLHIV) to be diagnosed, 90% of those diagnosed 
to receive antiretroviral treatment (ART) and 90% of 
those receiving treatment to achieve viral suppression, 
by 2020 [1]. Here, we describe progress towards the 
UNAIDS 90–90–90 targets across Europe and Central 
Asia and discuss whether current performance is suf-
ficient to eliminate HIV transmission.
The Dublin Declaration on Partnership to 
Fight HIV/AIDS
Between January and March 2018, the European 
Centre for Disease Prevention and Control (ECDC) 
disseminated an online survey to the 55 countries 
of Europe and Central Asia that comprise the World 
Health Organization (WHO) European Region, to moni-
tor the implementation of the Dublin Declaration on 
Partnership to Fight HIV/AIDS [2]. Countries provided 
estimates of the number and proportion of people 
within a defined four-stage continuum of care for the 
most recent year available (Box) [3,4].
 Countries also specified the year to which the esti-
mates related, data sources and collection methods 
and uncertainty bounds for each continuum stage. 
Where necessary, data were supplemented using 
Global AIDS Monitoring (GAM) indicators collected by 
UNAIDS. Data were validated by countries between 
May and November 2018 and updated accordingly.
Definitions and analyses
The global 90–90–90 targets are assessed as per-
centages of each previous stage of the continuum. 
The ‘substantive target’ is defined as the percentage 
of all PLHIV who are virally suppressed, making 73% 
the target (Figure 1). The global targets include coun-
tries reporting at least two consecutive stages but the 
substantive target only includes countries reporting 
all four stages of the continuum. Data were presented 
by WHO European subregion (West, Centre and East) 
which categorises countries in Europe and Central Asia 
in to three geographic areas by HIV epidemic type [5]. 
At the (sub)regional level, analyses were undertaken 
after summing each continuum stage across countries 
[3]. Data were compared with that previously submit-
ted through the Dublin Declaration survey [3,6,7]. 
Key findings
In 2018, 52 of 55 countries completed the survey with 
34 providing data across all four continuum stages 
(compared with 29 in 2016) and 42 providing at least 
two consecutive stages (compared with 41 in 2016). In 
2018, progress towards the global 90–90–90 targets 
in Europe and Central Asia stands at 80%–64%–86%. 
In the West subregion, 87%–91%–93% was achieved 
with equivalent figures at 83%–73%–75% and 76%–
46%–78% in the Centre and East, respectively. In coun-
tries in the European Union/European Economic Area 
(EU/EEA), which includes countries from each of the 
subregions, the progress stands at 86%–91%–92%. 
The number and proportion in each continuum stage 
are presented in the Table.
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For countries that provided data for both years (n = 25), 
performance can be compared between 2016 and 2018 
(Figure 2); outcomes improved from 82%–85%–89% 
to 85%–89%–91% for the global targets, respectively. 
Overall 69% of all PLHIV were virally suppressed in 
2018 compared with 62% in 2016. Improvements in the 
substantive targets were observed in all subregions 
(the 1% decline in percentage diagnosed in the Centre 
subregion is likely due to a revision of the estimate 
of undiagnosed PLHIV). Viral suppression among all 
PLHIV was 74% (West), 45% (Centre) and 25% (East) 
in 2018, compared with 67%, 34% and 16% in 2016, 
respectively.
The number of people with transmissible levels of virus 
can be calculated by adding the number of PLHIV esti-
mated to be undiagnosed, diagnosed but untreated 
and treated but not virally suppressed (for countries 
providing all four stages. An estimated 57% (1.2 mil-
lion/2.1 million) PLHIV are presumed to have transmis-
sible levels of virus in 2018. Of which, an estimated 
36% were undiagnosed, 51% were diagnosed but 
untreated and 13% were treated but had unsuppressed 
viral load (Figure 3). By subregion, 16% of people with 
presumed transmissible levels of virus lived in the 
West, 1% in the Centre and 83% in the East. Excluding 
Russia (which constituted 60% of all PLHIV with trans-
missible levels of virus in the entire Region) the figures 
become 41%, 3% and 56%, respectively.
Discussion
There has been substantial progress towards achieving 
the global UNAIDS targets across Europe and Central 
Asia and improvements have been recognised across 
all three WHO subregions. Despite this, only two-fifths 
of all PLHIV across the Region are estimated to be 
virally suppressed in 2018. While the West subregion 
exceeded the 73% substantive target, only around a 
half (Centre) and a quarter (East) of PLHIV are virally 
suppressed. The substantial progress between 2016 
and 2018 is indicative of the improvements that can be 
made on a Regional scale in a short amount of time; 
this should provide reassurance and incentive to other 
global Regions that still have much work in order to 
meet the 90–90–90 ambition [8].
Each country should assess its progress against 
90–90–90 targets and compare outcomes against 
Regional performance to drive further improvement. 
Only 34 of 55 countries provided data on all four con-
tinuum stages. Improved data availability is crucial to 
better monitor the effectiveness of their public health 
response to HIV. Countries that are unable to monitor 
the continuum of care need support to develop the 
infrastructure and data flows to enable them to do so.
Improvements in ART access are likely to have positively 
influenced the outcomes. Four countries recommended 
ART initiation regardless of CD4+  cell count (‘test and 
treat’) in 2014, 16 in 2016 and 14 in 2018. Treatment 
Box
Four-stage continuum of HIV care, global UNAIDS 90-
90-90 target and substantive target 
Stage 1: Estimated number of people living with HIV
Stage 2: Number/percentage of stage 1 diagnosed
Stage 3: Number/percentage of stage 2 receiving ART
Stage 4: Number/percentage of stage 3 with viral load < 200 
copies/mL (considered as virally suppressed)
• Global UNAIDS 90-90-90 target:
First 90: Number/percentage of all PLHIV who are 
diagnosed
Second 90: Number/percentage of those diagnosed who 
are treated
Third 90: Number/percentage of those treated who are 
virally suppressed
• Substantive target:
Number/percentage of all PLHIV who are virally 
suppressed.
ART: antiretroviral therapy; PLHIV: people living with HIV.
Source: Gourlay et al [4]
Figure 1
The continuum of HIV care as envisaged by the 90–90–90 
UNAIDS targets by 2020
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reported only where available.
Graph is adapted from [1].
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Table a
Progress against the global 90–90–90 targets reported, European and Central Asian countries, 2018 (n = 52)
WHO 
subregion Country
Total numbers Global 90–90–90 Targets Substantive Target
All PLHIV Diagnosed Treated Virally suppressed
% of 
PLHIV 
who are 
diagnosed
% of 
diagnosed 
PLHIV 
who are 
receiving 
ART
% receiving 
ART who 
are virally 
suppressed
% of PLHIV 
who are virally 
suppressed
2020 
target: 
90%
2020 
target: 
90%
2020 target: 
90%
2020 target: 
73%
West 
 
(n=23 
countries)
Andorra NA 68 68 NA NA 100 NA NA
Austria 7,079 6,537 6,145 5,223 92 94 85 74
Belgium 18,758 15,885 13,763 12,759 85 87 93 68
Denmark 6,000 5,500 5,300 5,200 92 96 98 87
Finland 3,880 3,401 NA NA 88 NA NA NA
France 156,600 132,400 120,700 116,600 85 91 97 74
Germany 86,100 74,800 68,800 65,500 87 92 95 76
Greece 16,665 13,866 9,594 NA 83 69 NA NA
Iceland NA NA NA NA NA NA NA NA
Ireland 7,205 6,276 5,227 4,986 87 83 95 69
Israel 8,039 7,448 5,087 NA 93 68 NA NA
Italy 130,000 114,400 100,000 87,000 88 87 87 67
Liechtenstein NA NA NA NA NA NA NA NA
Luxembourg 1,081 919 812 751 85 88 92 69
Malta 453 340 340 298 75 100 88 66
Monaco 47 47 47 47 100 100 100 100
The Netherlands 22,900 20,264 18,599 17,580 88 92 95 77
Norway NA NA NA NA NA NA NA NA
Portugal 38,959 35,709 31,000 28,007 92 87 90 72
Spain 146,000 120,000 116,408 103,000 82 97 88 71
Sweden 8,320 7,489 7,261 6,930 90 97 95 83
Switzerland 16,600 15,000 14,400 13,900 90 96 97 84
United Kingdom 101,400 91,987 88,089 85,446 91 96 97 84
West totala 776,086 672,336 611,640 553,227 87 91 93 74
Centre 
 
(n=15 
countries)
Albania 1,300 891 568 312 69 64 55 24
Bulgaria 2,862 2,410 1,198 689 84 50 58 24
Croatia 1,533 1,077 919 822 70 85 89 54
Cyprus NA NA NA NA NA NA NA NA
Czech Republic 3,230 2,533 1,800 1,660 78 71 92 51
Hungary NA NA NA NA NA NA NA NA
Kosovo* NA NA NA 15 NA NA NA NA
The former Yugoslav 
Republic of 
Macedonia,
383 246 198 191 64 80 96 50
Montenegro 437 201 140 121 46 70 86 28
Poland NA NA NA NA NA NA NA NA
Romania 17,000 15,009 11,570 8,409 88 77 73 49
Serbia 2,700 2,441 1,724 NA 90 71 NA NA
Slovakia 995 756 540 NA 76 71 NA NA
Slovenia 987 670 533 530 68 80 99 54
Turkey NA NA NA NA NA NA NA NA
Centre totala 31,427 26,234 19,190 12,749 83 73 75 46
ART: antiretroviral therapy; NA: Not available; PLHIV: people living with HIV; WHO: World Health Organization.
a Totals reflect sum of values presented. However only countries with data for consecutive stages of the continuum are included in the global 
90–90–90 target outcomes and only countries with all four elements are included in substantive target outcome.
* This designation is without prejudice to positions on status, and is in line with UNSC 1244 and the ICJ Opinion on the Kosovo Declaration of 
Independence.
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coverage among the diagnosed population was 89% 
for countries implementing ‘test and treat’ in 2014, 
93% in 2016 and 46% in 2018. This, together with the 
significant variation in outcomes across countries and 
subregions (including those with similar contexts and 
epidemics) demonstrates the powerful impact of policy 
implementation. The substantial drop-off between the 
percentages diagnosed and treated in the East subre-
gion is concerning since it enables preventable deaths, 
serious illness and onward transmission.
Characterising the population living with transmissible 
virus provides new insight into the scale and focus of 
prevention efforts. Almost two-thirds of the 1.2 million 
people with transmissible virus across the Region are 
diagnosed. This indicates that the biggest public health 
impact could be achieved through rapid and sustained 
scale up of treatment, particularly in the Centre and 
East subregions. Across the Region, the large undiag-
nosed population can be addressed by diversifying 
and augmenting policies offering HIV tests: for indi-
cator conditions, during screenings for other sexually 
transmitted infections, in community-based settings, 
as self/home-testing and for partner notification. New 
European guidance on setting-based approaches for 
HIV and hepatitis testing can help countries implement 
more effective testing programmes [9].
It is unclear whether current progress has impacted on 
HIV transmission. Recent modelling suggests a viral 
suppression rate of 90% among all PLHIV must be 
reached to reduce incidence [10]. This indicates inten-
sive efforts are required before transmission begins to 
fall. However, the West subregion, which has met the 
substantive target, has provided a favourable context 
in which reductions in HIV transmission are apparent 
among gay and bisexual men in some settings [11-14]. 
It is likely further declines will be observed when pre-
exposure prophylaxis (PrEP) is fully implemented to 
those most at need.
The 90–90–90 targets remain a powerful tool to assess 
progress towards HIV elimination and drive standards 
in care for PLHIV. However, they cannot provide a 
WHO 
subregion Country
Total numbers Global 90–90–90 Targets Substantive Target
All PLHIV Diagnosed Treated Virally suppressed
% of 
PLHIV 
who are 
diagnosed
% of 
diagnosed 
PLHIV 
who are 
receiving 
ART
% receiving 
ART who 
are virally 
suppressed
% of PLHIV 
who are virally 
suppressed
2020 
target: 
90%
2020 
target: 
90%
2020 target: 
90%
2020 target: 
73%
East 
 
(n=14 
countries)
Armenia 3,400 2,265 1,530 1,304 67 68 85 38
Azerbaijan 8,003 5,661 4,207 1,778 71 74 42 22
Belarus 26,120 19,231 11,242 7,253 74 58 65 28
Estonia 7,900 NA 4,109 NA NA NA NA NA
Georgia 10,500 5,090 4,144 3,383 48 81 82 32
Kazakhstan 26,000 20,841 11,482 6,338 80 55 55 24
Kyrgyzstan 8,500 5,805 3,237 1,995 68 56 62 23
Latvia NA NA NA NA NA NA NA NA
Lithuania 2,761 2,601 780 609 94 30 78 22
Moldova 15,132 11,887 5,162 3,324 79 43 64 22
Russia 998,525 808,823 319,613 27,1671 81 40 85 27
Tajikistan 15,000 7516 4,942 NA 50 66 NA NA
Ukraine 244,000 136,378 98,237 57,010 56 72 58 23
Uzbekistan NA 21,364 20,281 17,530 NA 95 86 NA
East totala 1,365,841 1,047,462 488,966 372,195 76 46 78 26
Total (Tables A and 
B)a 2,173,354 1,746,032 1,119,796 938,171 80 64 86 43
ART: antiretroviral therapy; NA: Not available; PLHIV: people living with HIV; WHO: World Health Organization.
a Totals reflect sum of values presented. However only countries with data for consecutive stages of the continuum are included in the global 
90–90–90 target outcomes and only countries with all four elements are included in substantive target outcome.
* This designation is without prejudice to positions on status, and is in line with UNSC 1244 and the ICJ Opinion on the Kosovo Declaration of 
Independence.
Table b
Progress against the global 90–90–90 targets reported, European and Central Asian countries, 2018 (n = 52)
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comprehensive picture of the public health response 
to HIV. While testing and treatment access are a clear 
focus, deaths and key interventions such as condom 
use, PrEP and health promotion are excluded. Results 
are limited in their representativeness, since only 34 
countries provided information for all four stages of the 
continuum with only 25 providing data for both 2016 
and 2018. Furthermore, while continuum methods have 
been defined, in practice, variations in data availabil-
ity, sources, timeframes and analysis (such as abil-
ity to account for deaths and loss-to-follow-ups) limit 
direct comparisons. Stage 1 of the continuum is, by 
necessity, an estimation. It is the part of the continuum 
that is simultaneously most vulnerable to uncertainty 
and the most critical since it sets the denominator 
upon which the 90–90–90 targets are calculated [4]. 
The estimated number of PLHIV (including number with 
transmissible virus) underrepresents the true Regional 
situation since they are presented only where countries 
report data.
Figure 2
Continuum of HIV care (substantive target), overall and by WHO subregion, 2018, and comparison between 2018 and 
2016a,b
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A major limitation is that percentage values mask abso-
lute numbers of PLHIV. We recommend that assess-
ment of the 90–90–90 targets must incorporate the 
number of PLHIV. The analysis of the estimated num-
ber of people living with transmissible levels of virus 
provides further insights. For instance, the high pro-
portion of people with transmissible virus is exacer-
bated by the large size of the Russian and Ukrainian 
epidemic. Furthermore, in the United Kingdom, France 
and Germany, the proportion of people with transmis-
sible HIV is low but masks significant absolute num-
bers, which impedes efforts to reduce HIV incidence. It 
is also important to ascertain outcomes for key popula-
tions which are known to experience stark inequalities 
within and between countries [15].
It is crucial not to rest content with meeting the 
90–90–90 targets. Each ‘last 10 percent’ includes peo-
ple especially marginalised from healthcare services. 
Beyond the 90–90–90 ambition, intensive efforts in 
policy and service implementation are vital if the ulti-
mate aim of ‘getting to zero’ is to become reality.
*This designation is without prejudice to positions 
on status, and is in line with UNSC 1244 and the ICJ 
Opinion on the Kosovo Declaration of Independence.
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Distribution of people with transmissible levels of virus, by WHO subregiona, and Europe and Central Asia overall, 2018
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